Literature DB >> 15736109

Carotid artery intima-media thickness and lipid profile in adults with growth hormone deficiency after long-term growth hormone replacement.

Débora Vieira Soares1, Luciana Diniz Carneiro Spina, Rosane Resende de Lima Oliveira Brasil, Eliane Maria Carvalho da Silva, Priscila Marise Lobo, Elizabeth Salles, Claúdia Medina Coeli, Flávia Lúcia Conceição, Mario Vaisman.   

Abstract

To investigate the effects of growth hormone (GH) replacement on carotid artery intima-media thickness (IMT) and lipid profile, 29 adults with GH deficiency (GHD), mean age 42.5 +/- 10.1 years, were studied and compared with 29 control subjects matched for sex, age, body mass index, and smoking habits. Lipid profile (total cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein cholesterol, apolipoproteins A and B, and lipoprotein), serum insulin-like growth factor 1 (IGF-1) levels, and ultrasonography of the carotid arteries were performed at baseline and at 6, 12, and 24 months during GH therapy on maintenance dose. At baseline, when compared with the control group, patients presented increased carotid artery IMT (P < .05) and triglyceride levels (P < .001) and lower HDL concentrations (P < .01). In a linear regression analysis, age and known mean duration of GHD were correlated with carotid artery IMT. After 24 months of GH replacement, a reduction in the mean of carotid artery IMT was observed (P < .01). The apolipoprotein B levels decreased significantly after the first 3 months of GH treatment (P < .001) and remained stable thereafter. Women also presented an increase in HDL cholesterol levels (P < .01). No differences were observed in the other lipids measured. Carotid artery IMT at baseline was inversely correlated with the change in carotid artery IMT (Delta = 24 months - baseline), r = 0.63, P < .001. In conclusion, 24 months of GH replacement therapy promoted favorable effects on carotid artery IMT and lipid profile in patients with GHD. Long-term follow-up studies are required to show whether these beneficial effects will result in reduction of morbidity and mortality from vascular disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15736109     DOI: 10.1016/j.metabol.2004.09.011

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

1.  Two years of growth hormone replacement therapy in a group of patients with Sheehan's syndrome.

Authors:  Débora Vieira Soares; Luciana Diniz Carneiro Spina; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Elizabeth Salles; Claúdia Medina Coeli; Flávia Lúcia Conceição; Mario Vaisman
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

2.  Effects of thyroxine replacement on endothelial function and carotid artery intima-media thickness in female patients with mild subclinical hypothyroidism.

Authors:  Monica Dias Cabral; Patricia Teixeira; Debora Soares; Sandra Leite; Elizabeth Salles; Mario Waisman
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

3.  Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial.

Authors:  Janet Lo; Sung Min You; Bridget Canavan; James Liebau; Greg Beltrani; Polyxeni Koutkia; Linda Hemphill; Hang Lee; Steven Grinspoon
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

4.  GH/GHRH axis in HIV lipodystrophy.

Authors:  Takara L Stanley; Steven K Grinspoon
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

5.  Carotid Intima Media Thickness Is Independently Associated with Male Gender, Middle Age, and IGF-1 in Metabolically Healthy Obese Individuals.

Authors:  Hala Abd El-Hafez; Mohamed M Elrakhawy; Azza A El-Baiomy; Mervat M El-Eshmawy
Journal:  ISRN Obes       Date:  2014-01-28

Review 6.  Detection of metabolic syndrome features among childhood cancer survivors: a target to prevent disease.

Authors:  Adriana Aparecida Siviero-Miachon; Angela Maria Spinola-Castro; Gil Guerra-Junior
Journal:  Vasc Health Risk Manag       Date:  2008
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.